Acceleron Pharma Inc

Acceleron Pharma — Investor Presentation (January 2019)

39 slides from Acceleron Pharma's investor presentation, Jan 7, 2019

  1. Slide 1: Corporate Presentation

    Exhibit 99.1 Corporate Presentation January 7, 2019 1

  2. Slide 2: Forward-Looking Statements

    Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company

  3. Slide 3: Mission and Therapeutic Area Focus

    Mission and Therapeutic Area Focus HEMATOLOGY Our mission is to transform the lives NEUROMUSCULAR of patients with serious and rare diseases PULMONARY 3

  4. Slide 4: Building Therapeutic Area Leadership

    Building Therapeutic Area Leadership HematologyHHematollogy HEMATOLOGY NEUROMUSCULAR PULMONARY LuspaterceptLusppaterceptp Phase 3 Trials--Luspatercept Phase 2 Trials Phase 2 Trials--Sotatercept Lower-Risk MDS, RS+ ACE-083 Facioscapulohumeral muscular dystrophy (FSHD) Pulmonary arterial hypertension

  5. Slide 5: 2018 Key Milestones Across Therapeutic Areas

    2018 Key Milestones Across Therapeutic Areas Luspatercept ACE-083 Sotatercept Positive MEDALIST and BELIEVE Positive Part 1 results in CMT and PULSAR Phase 2 trial initiated Phase 3 trial results FSHD Phase 2 trials Multiple preclinical presentations ASH 2018 – MEDALIST and Presentations at multiple

  6. Slide 6: Anemia impacts approximately 25% of the population

    Anemia impacts approximately 25%1 of the population, or >1.5b people worldwide Hematology 1. de Benoist B et al., eds. Worldwide prevalence of anaemia 1993-2005. WHO Global Database on Anaemia Geneva, World Health Organization, 2008

  7. Slide 7: Chronic Anemia Due to Rare Blood Disorders

    Chronic Anemia Due to Rare Blood Disorders LOWER-RISK MDS Bone marrow failure disorder BETA-THALASSEMIA CHRONIC Genetic hemoglobin mutation ANEMIA MYELOFIBROSIS Fibrotic bone marrow disease 7

  8. Slide 8: Anemia's Impact on Patients

    Anemia’s Impact on Patients Fatigue/tiredness/weaknessdness/weakness Shortness off breathbreath/dizziness/dizziness Reduced mentalntal sharpnesssharpness Impact on dailyaily activitactivityy level Regular red bbloodlood cell transfusions 8

  9. Slide 9: Burden of Red Blood Cell Transfusion

    Burden of Red Blood Cell Transfusion Process Blood donation Processing, testing, Storage Distribution & packaging 6ම ĨŽƌчϰϮĚĂLJƐ Patient with chronic Red Blood Cell Iron Overload anemia hits Cross-match Transfusion Infection hemoglobin threshold Appointment Decreased Mortality Appointment Alloim

  10. Slide 10: Lack of Viable Treatment Options

    Lack of Viable Treatment Options 1989 > 30 years 2020 Synthetic Potential erythropoietin No new product approvals to treat Luspatercept approved for lower-risk MDS-, beta-thalassemia-, and/or U.S. / E.U. market certain anemias myelofibrosis-associated anemia in the U.S. approval 10

  11. Slide 11: Luspatercept: A First-in-Class Erythroid Maturation Agent

    Luspatercept: A First-in-Class Erythroid Maturation Agent 6WHP 3URJHQLWRU &HOO &HOOV (U\WKUREODVWPDWXUDWLRQLQWRUHGEORRGFHOOV TGF-BETA PROTEINS LUSPATERCEPT 11

  12. Slide 12: MEDALIST and BELIEVE Phase 3 Trial Results

    MEDALIST and BELIEVE Phase 3 Trial Results Phase 3 Phase 3 Lower-Risk MDS, RS+ ɴ-Thalassemia, Transfusion-Dependent ƒ ASH 2018 plenary and oral presentations selected for “Best of ASH” ƒ Luspatercept met all primary and key secondary endpoints ƒ Durable responses with a favorable safety profile ƒ Pl

  13. Slide 13: Additional Luspatercept Trials Underway

    Additional Luspatercept Trials Underway Phase 3 Phase 2 Phase 2 Lower-Risk MDS, First-line ɴ-Thalassemia, Non- Transfusion-Dependent ƒ Enrolling up to 350 ƒ Enrolling up to 150 ƒ Enrolling up to 70 patients patients patients New trials supported by Phase 2 results 56%1 53%2 шϯϬй3 RBC Transfusion Ind

  14. Slide 14: A Potential Platform Treatment for Chronic Anemias

    A Potential Platform Treatment for Chronic Anemias Evaluating additional Lower-Risk MDS Lower-Risk MDS ɴ-Thalassemia ɴ-Thalassemia, diseases RS+ First-line Transfusion-Dependent Non-Transfusion- associated with Dependent anemia $2 Billion + $1 Billion + + TBD Estimated Estimated Annual Peak Annual P

  15. Slide 15: Luspatercept's Potential Revenue Drives Significant Value

    Luspatercept’s Potential Revenue Drives Significant Value Acceleron Receives Royalty % Low to Mid-20s Celgene Funds Program Costs ~100% Potential Acceleron Annual Royalty Revenue Annual Peak Sales Potential Scenarios 15

  16. Slide 16: Neuromuscular Disease

    ly Vy Neuromuscular Disease

  17. Slide 17: ACE-083: Targeting Focal Muscle Disease

    ACE-083: Targeting Focal Muscle Disease Administered into target Facioscapulohumeral Charcot-Marie-Tooth muscle for concentrated effect Muscular Dystrophy (FSHD) Disease (CMT) ACE-083 Myopathy Neuropathy Locally-acting ƒ 20,000 U.S. patients ƒ > 100,000 U.S. patients myostatin+ 17

  18. Slide 18: High Unmet Medical Need in FSHD and CMT

    High Unmet Medical Need in FSHD and CMT ƒ Slowly progressing muscle weakness diseases – Patients are typically diagnosed at a young age (20s to 30s) – Muscle weakness can progress asymmetrically ƒ No approved pharmacology solutions – Treatment is currently limited to physical therapy and bracing ƒ F

  19. Slide 19: Two-Part Phase 2 Trials in FSHD and CMT

    Two-Part Phase 2 Trials in FSHD and CMT PART 1 RESULTS ƒ Mean total muscle volume increases (14% to 20%)* ƒ Reduction in absolute fat fraction (overall muscle quality improvement)* ƒ No serious adverse events, most common adverse events were mild or moderate (grades 1-2)* PART 2FSHD* OF EACH PHASE 2

  20. Slide 20: Pulmonary Disease

    Pulmonary Disease

  21. Slide 21: Pulmonary Arterial Hypertension (PAH) Disease Background

    Pulmonary Arterial Hypertension (PAH) Disease Background Symptoms PATIENT SNAPSHOT mean ƒ Shortness of breath age 50 ƒ Chest pain ƒ Dizziness and/or fainting 3 to 1 ƒ Exertion fatigue 70K women to men U.S./E.U. PAH Patients 21

  22. Slide 22: Current Therapies Are Not Enough

    Current Therapies Are Not Enough DRUG APPROVALS 14 disease modifying over the last 20 YEARS NO therapies Improved survival and quality of life Median survival ~5 to 7 years 22

  23. Slide 23: PAH: A Disease of Vascular Remodeling

    PAH: A Disease of Vascular Remodeling Pulmonary Arteries Elevated pressure in the pulmonary circulation leads to heart failure Normal Arterial Hypertension • Smooth muscle cell hypertrophy • Endothelial cell proliferation • Intimal fibrosis 23

  24. Slide 24: Sotatercept's Activity in Preclinical Studies

    Sotatercept’s Activity in Preclinical Studies Sotatercept1 Preclinical Study: Sugen Hypoxia Model Lung histology Pulmonary Arterioles (10-50 μm, N=100) Classification (%)2 ;ɲ^DͬĞůĂƐƚŝŶƐƚĂŝŶŝŶŐ͕ϭϬyŵĂŐŶŝĨŝĐĂƚŝŽŶͿ % of Completely Muscularized Vessels 72.5% 29.3% Vehicle Sotatercept1 Vehicle Sotater

  25. Slide 25: PAH Phase 2 Trials Ongoing and Planned

    PAH Phase 2 Trials Ongoing and Planned Traditional Phase 2 Trial Exploratory Phase 2 Trial Randomized, double blind, placebo-controlled Open-label, single arm N = 100 N = 25 6-month primary treatment period: 6-month primary treatment period endpoints: ƒ Primary endpoint: pulmonary vascular resistanc

  26. Slide 26: Upcoming Corporate Priorities

    Upcoming Corporate Priorities HEMATOLOGY ƒ Luspatercept – Planned marketing authorization applications in US and EU for LR MDS and ɴ-thalassemia in 1H 2019 – MEDALIST and BELIEVE Phase 3 trial results planned to be submitted for publication in 2019 – COMMANDS Phase 3 clinical trial patient enrollmen

  27. Slide 27: Long-term Vision for Growth and Value Creation

    Long-term Vision for Growth and Value Creation ACE-083 (2019) Sotatercept (2020) • Phase 2 results expected in • PULSAR & SPECTRA Phase Luspatercept (2018) FSHD & CMT 2 results expected in PAH • Positive MEDALIST and BELIEVE Phase 3 trial results • COMMANDS and BEYOND trials initiated • Myelofibrosi

  28. Slide 28: Additional Slides

    Additional Slides

  29. Slide 29: ASH 2018: MEDALIST and BELIEVE Phase 3 Trial Results

    ASH 2018: MEDALIST and BELIEVE Phase 3 Trial Results 29

  30. Slide 30: MEDALIST Phase 3 Trial Design

    MEDALIST Phase 3 Trial Design Double-blind Screening Week 24 Week 48 luspatercept 16-week Treated Lower- confirmed SC Primary Secondary Risk MDS transfusion Every 3 Endpoint Endpoint burden Weeks (RS+) Placebo 2:1 Randomized ƒ Primary Endpoint – RBC-ƚƌĂŶƐĨƵƐŝŽŶŝŶĚĞƉĞŶĚĞŶĐĞ;шϴǁĞĞŬƐͿĚƵƌŝŶŐƚŚĞĨŝ

  31. Slide 31: MEDALIST Phase 3 Trial Primary Endpoint

    MEDALIST Phase 3 Trial Primary ŶĚƉŽŝŶƚ͗ZĞĚůŽŽĚĞůůdƌĂŶƐĨƵƐŝŽŶ/ŶĚĞƉĞŶĚĞŶĐĞшϴtĞĞŬƐ Luspatercept Placebo RBC-d/шϴǁĞĞŬƐ (n = 153) (n = 76) Weeks 1–24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2–46.1 6.5–22.9 P valuea < 0.0001 a Cochran–Mantel–Haenszel test stratified for average baseline RBC tr

  32. Slide 32: MEDALIST Secondary Endpoint: Erythroid Response (HI-E)

    MEDALIST Phase 3 Trial Secondary Endpoint: Erythroid Response (HI-E) Luspatercept Placebo (n = 153) (n = 76) Achieved HI-Ea (weeks 1–24), n (%) 81 (52.9) 9 (11.8) Reduction of ш4 RBC units/8 weeks (baseline transfusion burden ш4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) ,ďŝŶĐƌĞĂƐĞŽĨшϭ͘ϱŐͬĚ> (b

  33. Slide 33: BELIEVE Phase 3 Trial Design

    BELIEVE Phase 3 Trial Design Double-blind Weeks Weeks Screening 13 - 24 37 - 48 12-week luspatercept Treated prospective ɴ-Thalassemia SC Primary Secondary pre- Every 3 Endpoint Transfusion- treatment Endpoint Weeks Dependent period Placebo 2:1 Randomized ƒ Primary Endpoint – шϯϯйƌĞĚƵĐƚŝŽŶŝŶƚƌĂŶ

  34. Slide 34: BELIEVE Primary endpoint MET: Rate of Erythroid Response

    BELIEVE Phase 3 Trial Primary endpoint MET: Rate of Erythroid Response A significantly greater proportion of luspatercept-WUHDWHGSDWLHQWVDFKLHYHGD•UHGXFWLRQIURP baseline in transfusion burden during weeks 13 to 24 30 Luspatercept P < 0.0001 (OR 5.79, 95% CI 2.24–14.97) Placebo 25 20 15 21

  35. Slide 35: BELIEVE All key secondary endpoints MET

    BELIEVE Phase 3 Trial All key secondary endpoints MET: Rates of Erythroid Response A significantly greater proportion of luspatercept-treated patients achieved clinically meaningful reductions in WUDQVIXVLRQEXUGHQRI•DQG• 30 Luspatercept P < 0.0001a 25 Placebo 20 P = 0.0017c 15 P = 0.030

  36. Slide 36: BELIEVE Reduction in transfusion burden during any 12- and 24-week interval

    BELIEVE Phase 3 Trial Reduction in transfusion burden during ANY 12- and 24-week interval During any 12- or 24-week interval, a significantly greater proportion of luspatercept-treated patients DFKLHYHGFOLQLFDOO\PHDQLQJIXOUHGXFWLRQVLQWUDQVIXVLRQEXUGHQRI•DQG• Any 12-week interval An

  37. Slide 37: COMMANDS Phase 3 Trial Design

    COMMANDS Phase 3 Trial Design Open-label Screening luspatercept Weeks 0 - 24 Weeks 0 - 48 16-week (n = 175) Primary/ First-line, confirmed Secondary Secondary Lower- transfusion Endpoints Endpoints Risk MDS history epoetin alfa (n = 175) 1:1 Randomized ƒ Primary Endpoint – RBC-transfusion independen

  38. Slide 38: BEYOND Phase 2 Trial Design

    BEYOND Phase 2 Trial Design Double-blind Screening luspatercept Weeks 13 - 24 Weeks 37 - 48 (n = 100) ɴ-Thalassemia 4-week Primary Secondary Non-Transfusion- period Endpoint Endpoint Dependent Placebo (n = 50) 2:1 Randomized ƒ Primary Endpoint – WƌŽƉŽƌƚŝŽŶŽĨƉĂƚŝĞŶƚƐǁͬĐŽŶƚŝŶƵŽƵƐŝŶĐƌĞĂƐĞшϭ͘ϬŐͬ

  39. Slide 39: Myelofibrosis Phase 2 Trial Design

    Myelofibrosis Phase 2 Trial Design Luspatercept Monotherapy Cohort 1: Anemia Only (n = 20) 24 WEEKS ƒ ,ďчϵ͘ϱŐͬĚ>͕ŶŽZƚƌĂŶƐĨƵƐŝŽŶŝŶƉƌŝŽƌϴϰĚĂLJƐ Primary Endpoints Cohort 2: Transfusion Dependent (n = 20) ƒ Average of 2-4 RBC units / 4 weeks over 12 weeks Anemia Only Cohorts 1 & 3a: ƒ шнϭ͘ϱ

Acceleron Pharma — Investor Presentation (January 2019) on 6ix